T-Cell “Rejuvenation” Nanovaccine: Enhancing Immunological Memory and Antitumor Responses through Telomere Extension

This is the authors' abstract. We don't add key points for this paper.

Replicative senescence in immune cells undermines vaccine efficacy, with telomere attrition recognized as a key factor to cellular senescence. Studies have shown that the extracellular vesicles (EVs) of bone marrow-derived dendritic cells (BMDCs), which contain the telomeric compounds, can promote telomerase-independent T-cell telomere extension via telomere transfer. Based on this mechanism, we designed a long-term memory T-cell vaccine (LMT/OT-II), which is composed of EVs from BMDCs carrying the ovalbumin peptide OT-II. This vaccine not only enhances antigen presentation but also extends T-cell telomere length, enhancing T-cell vitality and restoring youthful characteristics. To further enhance the antitumor effects, we incorporated the immune adjuvant Poly(I:C) to activate T cells. In both young and aged mouse models, the LMT/OT-II + Poly(I:C) effectively suppressed the growth of B16-OVA melanoma and significantly prolonged the survival of the mouse models. We further developed the LMT/Adpgk + Poly(I:C) vaccine based on mouse colon cancer cell (MC38) neoantigen peptide, which also showed promising results in mice. Through telomere transfer to restore T-cell function and enhance immune memory, our study provides a novel and universal strategy for developing more effective and durable T-cell vaccines, particularly for diseases associated with immunosenescence.